Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting

• Published in: BMC cancer 2024-07, Vol.24 (1), p.867-10, Article 867
• Main Authors: Wang, Cong, Jiang, Zhansheng, Zhang, Jie, Zhuang, Yan, Sun, Lining, Zhang, Jing, Quan, Manman, Lan, Lan, Li, Yanwei, Wang, Bin, Pan, Zhanyu, Yan, Zhuchen
• Format: Article
• Language: English
• Subjects: Administration, Cutaneous; Adult; Aged; Antiemetics; Antiemetics - administration & dosage; Antiemetics - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer; Capecitabine; Capecitabine - administration & dosage; Capecitabine - adverse effects; CapeOX regimen; Central nervous system depressants; Chemotherapy; Chemotherapy-induced nausea and vomiting; Complications and side effects; Constipation; Dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - therapeutic use; Drug delivery; Drug dosages; Female; Granisetron; Granisetron - administration & dosage; Granisetron - therapeutic use; Humans; Male; Malignancy; Middle Aged; Nausea; Nausea - chemically induced; Nausea - prevention & control; Oral administration; Oxaliplatin; Oxaliplatin - administration & dosage; Oxaliplatin - adverse effects; Patients; Prospective Studies; Quality of Life; Questionnaires; Skin; Software; Transdermal delivery system; Vomiting; Vomiting - chemically induced; Vomiting - drug therapy; Vomiting - prevention & control
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-12616-9

To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving Capecitabine plus Oxaliplatin (CapeOX) therapy. Open-label, prospective, multi-center phase II trial. Three institutions. Fifty-four patients scheduled to receive CapeOX chemotherapy. Participants received GTDS (3.1 mg applied to the upper arm 48 h before chemotherapy, replaced on day 5, and discarded on day 12) and Dexamethasone. The primary endpoint was the complete control rate of CINV. Secondary endpoints included the duration of delayed complete control, complete control rate in the acute phase, safety, and quality of life. The complete control rate for delayed CINV over the entire period (25-480 h) was 72.7% (95% CI 0.57-0.88). The duration of delayed complete control was 17.2 ± 4.5 days, with 51.5% of patients experiencing no nausea during the delayed phase. The complete control rate in the acute phase was 81.8% (95% CI 0.69-0.95). No serious adverse events related to the antiemetic regimen were reported. Prolonged administration of GTDS is safe and effective for preventing CINV in patients with gastrointestinal malignancies treated with CapeOX. ClinicalTrials.gov registry (NCT05325190); registered on October 10, 2021.